PGEN Share Price Performance
US$3.89
2.25 (137.20%)
54.2% undervalued intrinsic discount
US$8.50
Fair Value
Price US$3.89
AnalystConsensusTarget US$8.50
Fair ValueUS$8.50
Share Pricen/a
Precigen, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 39 Fair Values set on narratives written by author
PGEN Community Narratives
AN
Fair Value US$8.5 54.2% undervalued intrinsic discount
Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity
Catalysts About Precigen Precigen is a biotechnology company focused on developing and commercializing gene and immunotherapies such as PAPZIMEOS for patients with high unmet medical need. What are the underlying business or industry changes driving this perspective?Read more
76
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$8.5
54.2% undervalued intrinsic discount
Fair Value
Profit Margin
0.4%
Future PE
38.29x
Price in 2028
US$0.1
Trending Discussion
Recently Updated Narratives
AN
Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity
Fair Value: US$8.5 54.2% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Precigen, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.21
- 50.20%
- -4,436.62%
- 445.6%
About PGEN
- Founded
- 1998
- Employees
- 143
- CEO
- WebsiteView website
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
